Right on the heels of $150M raise, Ascentage files the latest in a rush of HKEX biotech IPOs — but is the market too jittery?
When I spoke to Ascentage CEO Dajun Yang last month about their $150 million raise, he dodged my question about the prospects for an IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
